
浏览全部资源
扫码关注微信
1.上海中医药大学附属龙华医院脾胃病研究所/经方与现代中药融合创新全国重点实验室(上海 200032)
2.上海中医药大学公共健康学院(上海 201203)
3.上海市宝山区中西医结合医院老年病科(上海 201999)
宋德济,男,硕士研究生,主要从事中医药防治慢性肝病研究工作
张莉,研究员,博士研究生导师;E-mail:lzhang0706@shutcm.edu.cn
收稿:2025-12-02,
纸质出版:2026-05-10
移动端阅览
宋德济,圣炜,张梓琪,等.基于Foxm1/NF‑κB轴探讨七味脂肝方改善饮食诱导小鼠代谢相关脂肪性肝炎的机制[J].上海中医药杂志,2026,60(5):68-76.
SONG Deji,SHENG Wei,ZHANG Ziqi,et al.Mechanism of Qiwei Zhigan Formula in ameliorating diet‑induced metabolic dysfunction⁃ associated steatohepatitis in mice: a study based on Foxm1/NF‑κB axis[J].Shanghai Journal of Traditional Chinese Medicine,2026,60(5):68-76.
宋德济,圣炜,张梓琪,等.基于Foxm1/NF‑κB轴探讨七味脂肝方改善饮食诱导小鼠代谢相关脂肪性肝炎的机制[J].上海中医药杂志,2026,60(5):68-76. DOI: 10.16305/j.1007-1334.2026.z20251202006.
SONG Deji,SHENG Wei,ZHANG Ziqi,et al.Mechanism of Qiwei Zhigan Formula in ameliorating diet‑induced metabolic dysfunction⁃ associated steatohepatitis in mice: a study based on Foxm1/NF‑κB axis[J].Shanghai Journal of Traditional Chinese Medicine,2026,60(5):68-76. DOI: 10.16305/j.1007-1334.2026.z20251202006.
目的
2
探究七味脂肝方(QWZG)改善饮食诱导的小鼠代谢相关脂肪性肝炎(MASH)的作用机制。
方法
2
采用西方饮食喂养诱导C57BL/6J雄性小鼠MASH模型。第18周成模后,小鼠随机分为模型组及QWZG低、中、高剂量干预组(
n
=8),另设对照组(
n=
8)。各干预组给予相应剂量QWZG灌胃6周,模型组及对照组给予等体积0.9%氯化钠溶液。治疗6周后测量各组小鼠体质量、肝质量、肝体比,检测血清中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆固醇(TC)和甘油三酯(TG)含量;通过苏木精-伊红(HE)染色法、油红O染色法评估小鼠肝组织病理学变化,采用免疫组化检测肝组织巨噬细胞浸润;利用转录组测序(RNA-seq)技术筛选QWZG影响的基因及通路,并运用Western blot法与逆转录实时定量聚合酶链反应(RT-qPCR)法对核心机制进行验证。
结果
2
与模型组相比,QWZG显著降低MASH小鼠的体质量、肝质量以及血清ALT、AST、TC、TG水平(
P
<
0.05),减轻肝脏脂肪变性和气球样变以及巨噬细胞浸润,RNA-seq结果显示QWZG干预显著下调小鼠肝脏叉头框蛋白M1(Foxm1)的表达,京都基因与基因组数据库(KEGG)富集分析发现QWZG能显著抑制核因子κB(NF-κB)信号通路、细胞因子-细胞因子受体信号传导等炎症相关通路,验证实验表明QWZG明显降低MASH小鼠Foxm1蛋白表达和p65磷酸化水平。
结论
2
QWZG改善小鼠MASH的作用机制可能与下调Foxm1并抑制NF-κB信号通路激活有关。
Objective
2
To investigate the mechanism of Qiwei Zhigan Formula (QWZG) in ameliorating diet-induced metabolic dysfunction-associated steatohepatitis (MASH) in mice.
Methods
2
A MASH model was established in male C57BL/6J mice by feeding a Western diet. After successful modeling at week 18, mice were randomly divided into a model group and QWZG low-, medium-, and high-dose intervention groups (
n
=8 per group), with a normal control group (
n
=8). Mice in the intervention groups received corresponding doses of QWZG by gavage for 6 weeks, while the model and control groups received an equal volume of 0.9% sodium chloride solution. After 6 weeks of treatment, body weight, liver weight, and liver-to-body weight ratio were measured; serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), and triglyceride (TG) were detected. Hepatic histopathological changes were assessed by hematoxylin-eosin (HE) staining and Oil Red O staini
ng, and hepatic macrophage infiltration was evaluated by immunohistochemistry. Transcriptome sequencing (RNA-seq) was used to identify genes and pathways modulated by QWZG, and Western blot and reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) were applied to validate the key mechanism.
Results
2
Compared with the model group, QWZG intervention significantly reduced body weight, liver weight, and serum levels of ALT, AST, TC, and TG in MASH mice (
P
<
0.05), and alleviated hepatic steatosis, ballooning degeneration, and macrophage infiltration. RNA-seq results showed that QWZG intervention significantly downregulated the expression of forkhead box protein M1 (Foxm1) in mouse liver. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that inflammatory-related pathways such as the nuclear factor‑κB (NF‑κB) signaling pathway and cytokine-cytokine receptor interaction were significantly inhibited. Validation experiments confirmed that QWZG intervention markedly decreased Foxm1 protein expression and p65 phosphorylation levels in MASH mice.
Conclusion
2
The mechanism by which QWZG ameliorates MASH in mice may be associated with downregulating Foxm1 and inhibiting the activation of the NF-κB signaling pathway.
杨蕊旭 , 范建高 . 欧洲代谢相关脂肪性肝病临床管理实践指南简介 [J]. 实用肝脏病杂志 , 2024 , 27 ( 5 ): 654 - 658 .
YOUNOSSI Z M , GOLABI P , PAIK J M , et al . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review [J]. Hepatology , 2023 , 77 ( 4 ): 1335 - 1347 .
范建高 , 徐小元 , 南月敏 , 等 . 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 实用肝脏病杂志 , 2024 , 27 ( 4 ): 494 - 510 .
SOHN W , LEE Y S , KIM S S , et al . KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 [J]. Clin Mol Hepatol , 2025 , 31 ( Suppl ): S1 - S31 .
European Association for the Study of the Liver (EASL) , European Association for the Study of Diabetes (EASD) , European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [J]. Obesity facts , 2024 , 17 ( 4 ): 374 - 444 .
杨嘉宁 , 赵一颖 , 肖伟 . 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 [J]. 药学实践与服务 , 2024 , 42 ( 9 ): 389 - 398 .
YANG M , QI X , LI N , et al . Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2‑oleoylglycerol [J]. Nat Commun , 2023 , 14 ( 1 ): 228 .
倪青 , 庞晴 . 代谢相关脂肪性肝病病证结合诊疗指南 [J]. 世界中医药 , 2024 , 19 ( 22 ): 3406 - 3419 .
吕婷婷 , 孙涛 , 李凯 , 等 . 吴明志运用柴胡郁金汤治疗非酒精性脂肪肝的临床经验 [J]. 中国现代医生 , 2020 , 58 ( 7 ): 137 - 140 .
中华中医药学会脾胃病分会 . 非酒精性脂肪性肝病中医诊疗专家共识(2023) [J]. 中国中西医结合消化杂志 , 2024 , 32 ( 1 ): 1 - 7 .
吴威 , 宋芷琪 , 田琨宇 , 等 . 豨桐丸的本草考证及组方药物化学成分和药理作用研究进展 [J]. 中草药 , 2020 , 51 ( 17 ): 4586 - 4597 .
杨迎迎 , 万新焕 , 刘英男 , 等 . 垂盆草化学成分及药理作用研究进展 [J]. 中国中药杂志 , 2020 , 45 ( 18 ): 4341 - 4348 .
吴明权 , 周许 , 彭伟 , 等 . 牡蛎性-效-用本草考证 [J]. 中华中医药杂志 , 2023 , 38 ( 7 ): 3123 - 3128 .
霍耀辉 , 张静 , 周立蓉 , 等 . 中医治疗冠心病合并高脂血症用药规律及机制的R语言和网络药理学分析 [J]. 华西药学杂志 , 2024 , 39 ( 6 ): 655 - 663 .
陈春燕 , 琚鹏磊 , 徐雨薇 , 等 . 海藻玉壶汤化裁治疗甲状腺肿的随机对照临床研究 [J]. 中华中医药学刊 , 2025 , 43 ( 11 ): 51 - 54 .
郭晨希 , 狄红杰 , 王丹 . 复方虎杖方治疗湿热蕴结型代谢相关脂肪性肝病的临床研究 [J]. 重庆医学 , 2025 , 54 ( 3 ): 606 - 611 .
徐子涵 , 刘雁峰 , 杨绿 , 等 . 《傅青主女科》中五味子的应用分析 [J]. 中华中医药杂志 , 2023 , 38 ( 12 ): 6079 - 6082 .
蒋丽娜 , 赵景民 . 代谢相关脂肪性肝病多器官损伤的病理机制 [J]. 临床肝胆病杂志 , 2025 , 41 ( 9 ): 1729 - 1736 .
TARU V , SZABO G , MEHAL W , et al . Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation [J]. J Hepatol , 2024 , 81 ( 5 ): 895 - 910 .
周岐鸣 , 宋海燕 , 刘洋 , 等 . 当飞利肝宁胶囊对CCl 4 诱导的非酒精性脂肪性肝病大鼠急性肝损伤肝组织SIRT1/NF-κB/p53信号通路的影响 [J]. 上海中医药杂志 , 2024 , 58 ( 5 ): 78 - 85 .
LIU T , ZHANG L , JOO D , et al . NF‑κB signaling in inflammation [J]. Signal Transduct Target Ther , 2017 , 2 : 17023 .
XU X , LEI Y , CHEN L , et al . Phosphorylation of NF‑κBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target [J]. J Exp Clin Cancer Res: CR , 2021 , 40 ( 1 ): 253 .
KURAHASHI T , YOSHIDA Y , OGURA S , et al . Forkhead Box M1 transcription factor drives liver inflammation linking to hepatocarcinogenesis in mice [J]. Cell Mol Gastroenterol Hepatol , 2020 , 9 ( 3 ): 425 - 446 .
YANG B , LU L , XIONG T , et al . The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis [J]. Nature communications , 2024 , 15 ( 1 ): 8388 .
LI X , CHEN F , JU J , et al . Long Non-Coding RNA-GDA-1 promotes keratinocyte proliferation and psoriasis inflammation by regulating the STAT3/NF-κB signaling pathway via Forkhead Box M1 [J]. Inflammation , 2023 , 46 ( 4 ): 1209 - 1220 .
LIU C , SHI J , LI Q , et al . STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer [J]. Clin Sci (Lond) , 2019 , 133 ( 5 ): 645 - 663 .
LIU J , NIU D , TANG Y , et al . Beta-hydroxy-beta-methylbutyrate (HMB) ameliorates DSS-induced colitis by inhibiting ERK/NF‑κB activation in macrophages [J]. Phytomedicine , 2025 , 139 : 156492 .
ZHANG P , CAO J , LIANG X , et al . Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis [J]. Acta Biochimica Biophys Sin , 2024 , 56 ( 4 ): 621 - 633 .
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构
沪公网安备 31011502015228号